These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27792005)

  • 1. Down-regulation of CYP27B1 gene expression in Iranian patients with relapsing-remitting multiple sclerosis.
    Rezaie Z; Taheri M; Kohan L; Sayad A
    Hum Antibodies; 2016; 24(3-4):71-76. PubMed ID: 27792005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Up regulation of MMP9 gene expression in female patients with multiple sclerosis.
    Hamedani SY; Taheri M; Sajjadi E; Omrani MD; Mazdeh M; Arsang-Jang S; Panah AS; Sayad A
    Hum Antibodies; 2016; 24(3-4):59-64. PubMed ID: 28128762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression ratio of matrix metalloproteinase-9 (MMP9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) RNA levels in Iranian multiple sclerosis patients.
    Nazdik MK; Taheri M; Sajjadi E; Arsang-Jang S; Koohpar ZK; Inoko H; Sayad A
    Hum Antibodies; 2016; 24(3-4):65-70. PubMed ID: 27689613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNAR1 expression level in Iranian multiple sclerosis patients treated with IFN-B.
    Sayad A; Kelarijani MK; Sajjadi E; Taheri M
    Hum Antibodies; 2017; 26(1):17-22. PubMed ID: 28282804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
    Samadzadeh S; Tabibian E; Sabokbar T; Shakoori A; Dehgolan SR; Armaki SA; Aslanbeigi B; Abolfazli R
    J Neurol Sci; 2015 May; 352(1-2):37-40. PubMed ID: 25824849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRAIL gene expression analysis in multiple sclerosis patients.
    Taheri M; Nemati S; Movafagh A; Saberi M; Mirfakhraie R; Eftekharian MM; Arsang-Jang S; Rezagholizadeh A; Sayad A
    Hum Antibodies; 2016 May; 24(1-2):33-8. PubMed ID: 27472871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
    Løken-Amsrud KI; Holmøy T; Bakke SJ; Beiske AG; Bjerve KS; Bjørnarå BT; Hovdal H; Lilleås F; Midgard R; Pedersen T; Benth JS; Sandvik L; Torkildsen O; Wergeland S; Myhr KM
    Neurology; 2012 Jul; 79(3):267-73. PubMed ID: 22700809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin D-related gene expression profiles in immune cells of patients with relapsing remitting multiple sclerosis.
    Smolders J; Thewissen M; Theunissen R; Peelen E; Knippenberg S; Menheere P; Cohen Tervaert JW; Hupperts R; Damoiseaux J
    J Neuroimmunol; 2011 Jun; 235(1-2):91-7. PubMed ID: 21507492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression Analysis of Long Non-coding RNA Lnc-DC in HLA-DRB1*15:01-Negative Patients with Multiple Sclerosis: A Probable Cause for Gender Differences in Multiple Sclerosis Susceptibility?
    Bahrami T; Taheri M; Javadi S; Omrani MD; Karimipour M
    J Mol Neurosci; 2021 Apr; 71(4):821-825. PubMed ID: 32951137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of RORA gene expression in the blood of multiple sclerosis patients.
    Sayad A; Salmani T; Hemmesi MK; Ganji M; Ghafouri-Fard S; Hatami M; Soudyab M; Taheri M
    Hum Antibodies; 2018; 26(4):219-224. PubMed ID: 29889063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A; Zhao Y; Karim ME; Evans C; Kingwell E; van der Kop ML; Oger J; Gustafson P; Petkau J; Tremlett H
    JAMA; 2012 Jul; 308(3):247-56. PubMed ID: 22797642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Association between vitamin D status and CYP27b1 and CYP24A1 gene polymorphisms in patients with multiple sclerosis in the Altai region].
    Smagina IV; Lunev KV; Elchaninova SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):61-66. PubMed ID: 32844632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VDBP, CYP27B1, and 25-Hydroxyvitamin D Gene Polymorphism Analyses in a Group of Sicilian Multiple Sclerosis Patients.
    Agnello L; Scazzone C; Lo Sasso B; Bellia C; Bivona G; Realmuto S; Brighina F; Schillaci R; Ragonese P; Salemi G; Ciaccio M
    Biochem Genet; 2017 Apr; 55(2):183-192. PubMed ID: 27904983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking affects the interferon beta treatment response in multiple sclerosis.
    Petersen ER; Oturai AB; Koch-Henriksen N; Magyari M; Sørensen PS; Sellebjerg F; Søndergaard HB
    Neurology; 2018 Feb; 90(7):e593-e600. PubMed ID: 29343473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitamin D and disability in relapsing-remitting multiple sclerosis in patients with a Mexican background.
    Rito Y; Flores J; Fernández-Aguilar A; Escalante-Membrillo C; Barboza MA; Amezcua L; Corona T
    Acta Neurol Belg; 2018 Mar; 118(1):47-52. PubMed ID: 28975580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of vitamin D receptor and metabolizing enzymes in multiple sclerosis-affected brain tissue.
    Smolders J; Schuurman KG; van Strien ME; Melief J; Hendrickx D; Hol EM; van Eden C; Luchetti S; Huitinga I
    J Neuropathol Exp Neurol; 2013 Feb; 72(2):91-105. PubMed ID: 23334593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis: effects of IFN-β treatment on vitamin D levels in multiple sclerosis are modified by genetic variants.
    Fyfe I
    Nat Rev Neurol; 2014 Dec; 10(12):672. PubMed ID: 25366113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.